Yannick, 13, was blind before receiving Spark’s SPK-RPE65 gene therapy product candidate, which restored much of his sight.
Dr. Katherine High has pioneered the development of gene therapy for nearly two decades.
Gene therapy is giving Michael, 67, new hope for a life free from hemophilia B.
Spark to open permanent west Philadelphia headquarters.
The team at Spark Therapeutics has pioneered the development of gene therapy for nearly two decades. Our founding team has brought us closer to solving the most complex challenges facing the field, creating new opportunities for the patients we serve and for the industry at large. Learn how we’re working to spark the next wave in the gene therapy revolution.
Biopharmaceutical industry leaders Vin Milano and Lars Ekman recently joined the Spark board of directors. Their expertise will bring valuable guidance as Spark continues to progress our lead program, a pivotal Phase 3 clinical trial for inherited retinal dystrophies caused by mutations to the RPE65 gene. These degenerative eye diseases result in severe visual impairments, progressing ultimately to blindness.